Skip to main content

Amersham Pharmacia Extends Patent Complaint


LONDON--Amersham Pharmacia Biotech, jointly owned by Nycomed Amersham and Pharmacia and Upjohn, has extended its intellectual property action against Perkin-Elmer's Applied Biosystems Division to include Perkin-Elmer's new joint venture, Celera Genomics. The suit asserts infringement on Amersham's intellectual property in the area of energy transfer dyes, which Amersham said Perkin-Elmer launched several years after Amersham introduced Dyenamic ET dye primers. The new action is based on Celera's use of the dyes in connection with a new Perkin-Elmer Applied Biosystems sequencing instrument.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.